Expression of the decay-accelerating factor (CD55) in renal transplants-a possible prediction marker of allograft survival

Transplantation

Volumn 88, Issue 4, 2009, Pages 457-464

  Brodsky, Sergey V ^a   Nadasdy, Gyongyi M ^a   Pelletier, Ronald ^a   Satoskar, Anjali ^a   Birmingham, Daniel J ^a   Hadley, Gregg A ^a   Obeidat, Khaled ^a   Nadasdy, Tibor ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Antibody mediated rejection; Decay accelerating factor; Peritubular capillary; Renal graft survival

Indexed keywords

COMPLEMENT COMPONENT C4D; DECAY ACCELERATING FACTOR; HLA ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; ANTIGENS, CD55; BIOLOGICAL MARKERS; CAPILLARIES; COMPLEMENT C4B; COMPLEMENT PATHWAY, ALTERNATIVE; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; ISOANTIBODIES; KAPLAN-MEIERS ESTIMATE; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 70349096432     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b0517d     Document Type: Article

References (29)

1. Hoffmann EM. Inhibition of complement by a substance isolated from human erythrocytes. I. Studies on the site and mechanism of action. Immunochemistry 1969; 6: 391.
2. Hoffmann EM. Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action. Immunochemistry 1969; 6: 405.
3. Nicholson-Weller A,March JP,Rosen CE,et al.Surfacemembraneexpres-sion by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system. Blood 1985; 65: 1237.
4. Asch AS, Kinoshita T, Jaffe EA, et al. Decay-accelerating factor is present on cultured human umbilical vein endothelial cells. J Exp Med 1986; 163: 221.
5. Lublin DM, Lemons RS, Le Beau MM, et al. The gene encoding decay-accelerating factor (DAF) is located in the complement-regulatory locus on the long arm of chromosome 1. J Exp Med 1987; 165: 1731.
6. Smith LJ. Paroxysmal nocturnal hemoglobinuria. Clin Lab Sci 2004; 17: 172.
7. Miwa T, Maldonado MA, Zhou L, et al. Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms. Am J Pathol 2007; 170: 1258.
8. Collins AB, Schneeberger EE, Pascual MA, et al. Complement activation in acute humoral renal allograft rejection: Diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 2208.
9. Damman J, Schuurs TA, Ploeg RJ, et al. Complement and renal transplantation: From donor to recipient. Transplantation 2008; 85: 923.
10. Racusen LC, Haas M. Antibody-mediated rejection in renal allografts: Lessons from pathology. Clin J Am Soc Nephrol 2006; 1: 415.
11. Colvin RB. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046.
12. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753.
13. Crespo M, Pascual M, Tolkoff-Rubin N, et al. Acute humoral rejection in renal allograft recipients. I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652.
14. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation. II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13: 779.
15. Feucht HE, Mihatsch MJ. Diagnostic value of C4d in renal biopsies. Curr Opin Nephrol Hypertens 2005; 14: 592.
16. Brown KM, Sacks SH, Sheerin NS. Mechanisms of disease: The complement system in renal injury-New ways of looking at an old foe. Nat Clin Pract Nephrol 2007; 3: 277.
17. Kayler LK, Kiss L, Sharma V, et al. Acute renal allograft rejection: Diagnostic significance of focal peritubular capillary C4d. Transplantation 2008; 85: 813.
18. Satoskar AA, Lehman AM, Nadasdy GM, et al. Peritubular capillary C4d staining in late acute renal allograft rejection-Is it relevant? Clin Transplant 2008; 22: 61.
19. Smolenski RT, Forni M, Maccherini M, et al. Reduction of hyperacute rejection and protection of metabolism and function in hearts of human decay accelerating factor (hDAF)-expressing pigs. Cardiovasc Res 2007; 73: 143.
20. Garcia B, Sun HT, Yang HJ, et al. Xenotransplantation of human decay accelerating factor transgenic porcine kidney to non-human primates: 4 years experience at a Canadian center. Transplant Proc 2004; 36: 1714.
21. Sun H, Chen G, Liu W, et al. The influence of baseline expression of human decay accelerating factor transgene on graft survival and acute humoral xenograft rejection. Transplantation 2005; 80: 1331.
22. Gonzalez-Stawinski GV, Tan CD, Smedira NG, et al. Decay-accelerating factor expression may provide immunoprotection against antibody-mediated cardiac allograft rejection. J Heart Lung Transplant 2008; 27: 357.
23. Nadasdy GM, Bott C, Cowden C, et al. Comparative study of the detection of peritubulary capillaries C4d deposition in human renal allo-grafts using different methodologies. Hum Pathol 2005; 36: 1178.
24. Shimizu I, Smith NR, Zhao G, et al. Decay-accelerating factor prevents acute humoral rejection induced by low levels of anti-alphaGal natural antibodies. Transplantation 2006; 81: 95.
25. Pavlov V, Raedler H, Yuan S, et al. Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allo-graft rejection. J Immunol 2008; 181: 4580.
26. Finberg RW, White W, Nicholson-Weller A. Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J Immunol 1992; 149: 2055.
27. Thurman JM, Lucia MS, Ljubanovic D, et al. Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int 2005; 67: 524.
28. Yamada K, Miwa T, Liu J, et al. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol 2004; 172: 3869.
29. Pangburn MK. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases. J Immunol 1986; 136: 2216.